The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2025 | Hematocrit control among patients with high- or low-risk PV receiving SoC treatment in the US
Aaron Gerds, MD, Cleveland Clinic, Cleveland, OH, discusses a study evaluating hematocrit control among patients with high- and low-risk polycythemia vera (PV) receiving current standard of care (SoC) treatment in the United States, highlighting the challenges of maintaining hematocrit levels below 45% with current therapies. Dr Gerds notes that even with these treatments, many patients experience periods where their hematocrit levels are not well-controlled, which may increase the risk of thrombosis and other complications. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
